Holly Lewis, MD, PhD

Postdoctoral Fellow

Engineering biomaterials, culturing tolerance. Holly is an MD/PhD at Duke University Medical Center where she spent the last two years as a surgery resident, but she’s excited to be on sabbatical from the clinical realm. She brings to the Segura lab a breadth of clinical knowledge, including transplant surgery, surgical lymph node mapping, abdominal, breast and extremity surgery. Her interests include tissue engineering, reconstructive surgery and transgender health. She completed her MD and PhD at Emory University, focusing on cellular immunology, chemical biology, and mesenchymal stem cell therapy. Holly pursued her undergraduate at Harvard University, where she concentrated in Chemistry with a secondary field in Romance languages (Spanish, Portuguese, Catalan). Her scientific repertoire includes synthetic chemistry, human stem cell culture, flow cytometry, and mammalian models of skin and gut-antigen sensitization. She is excited to pursue her postdoc with Prof. Segura, supported by the Duke SCI-StAR R38/NIAID program. She is also mentored by faculty in Plastic Surgery, Immunology, and Transplant Surgery, as she aims to develop biomaterials for reconstructive skin grafting and transplantation tolerance.
Lewis HC, Cendales LC. “Vascularized composite allotransplantation in the United States: a retrospective analysis of OPTN data after five years of the Final Rule.” American Journal of Transplantation. 2020 Jun 2. 1-6. doi:10.1111/ajt.16086
Lewis HC, Chinnadurai R, Bosinger SE, Galipeau J. “The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells.” Oncotarget 2017 Nov 3;8(54): 91914-91927
Oyoshi MK, He R, Kanaoka Y, ElKhal A, Kawamoto S, Lewis CN, Austen KF, Geha RS. “Eosinophil-derived Leukotriene C4 Signals via Type 2 Cysteinyl Leukotriene Receptor to Promote Skin Fibrosis in a Mouse Model of Atopic Dermatitis.” Proceedings of the National Academy of Sciences (USA). 2012. 109(13): 4992-7.